PremiumCompany AnnouncementsXORTX Receives Nasdaq Notification for Minimum Bid Price Deficiency Xortx Therapeutics discloses Nasdaq notification regarding minimum bid price XORTX Therapeutics Releases Annual Information Form for 2024 PremiumThe FlyXortx Therapeutics commences gout program NDA discussions with FDA XORTX Therapeutics Engages Investors at Microcap Conference XORTX Announces Change of Auditor PremiumCompany AnnouncementsXORTX Therapeutics Welcomes New CFO Dr. Bumby Xortx Therapeutics appoints Bumby as Chief Financial Officer XORTX Therapeutics Unveils New Kidney Disease Discoveries